公开(公告)号：US20130123204A1

公开(公告)日：2013-05-16

申请号：US13735620

申请日：2013-01-07

申请人： Lain-Tze LEE ,  Shau-Feng CHANG ,  Chia-Yu LIN ,  Hui-Yen WU ,  Shu-Feng CHEN ,  Jinun-Ban YEH

发明人： Lain-Tze LEE ,  Shau-Feng CHANG ,  Chia-Yu LIN ,  Hui-Yen WU ,  Shu-Feng CHEN ,  Jinun-Ban YEH

IPC分类号： A61K31/352

CPC分类号： A61K31/352 ,  A61K31/353 ,  A61K36/15 ,  A61K36/185 ,  A61K36/45 ,  A61K36/73 ,  A61K36/87

摘要： The disclosure provides a method for treating hepatitis B, including: administering an effective amount of proanthocyanidins wherein the formula of a monomer of the proanthocyanidins is shown as Formula (I): wherein R1 is OCH3, R2 is OH and R3 is H, or R1 is OH and R2 and R3 both are H, or R1 and R2 both are OH and R3 is H, or R1, R2 and R3 all are OH, and R4 is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar or 3-(β)-O-sugar. Bonding between adjacent monomers take place at C4, C8 Carbon-carbon bond or C2, C7 oxygen bond of A type or C4, C8 or C4, C6 Carbon-carbon bond of B type or C type of proanthocyanidins. And the polymerized number is from 2 to 30.

摘要翻译： 本发明提供了一种治疗乙型肝炎的方法，包括：给予有效量的原花青素，其中原花青素单体的式如式（I）所示：其中R1是OCH3，R2是OH，R3是H，或R1 是OH，R 2和R 2都是H，或者R 1和R 2都是OH，R 3是H，或者R 1，R 2和R 3都是OH，R 4是3-（α）-OH，3-（β）-OH ，3-（α）-O-糖或3-（β）-O-糖。 相邻单体之间的键合发生在C4，C8碳 - 碳键或A型的C2，C7氧键或C4，C8或C4，C6B型或C型原花色素的碳 - 碳键。 聚合数为2〜30。

公开(公告)号：US20100317637A1

公开(公告)日：2010-12-16

申请号：US12573116

申请日：2009-10-04

申请人： Lain-Tze LEE ,  Shau-Feng CHANG ,  Hui-Ping TSAI ,  Zong-Keng KUO ,  Chen-Fang CHUNG

发明人： Lain-Tze LEE ,  Shau-Feng CHANG ,  Hui-Ping TSAI ,  Zong-Keng KUO ,  Chen-Fang CHUNG

IPC分类号： A61K31/58 ,  C07J71/00 ,  A61P31/12

CPC分类号： A61K31/58 ,  C07J71/0005 ,  C07J71/0021

摘要： The invention provides an anti-hepatitis C composition including: an effective amount of limonoid compound, wherein the structure of the limonoid compound is shown as Structure (I): where R1 comprises H or OAc and R2 comprises H or COCH(CH3)2; and a pharmaceutically acceptable carrier or salt, and the anti-hepatitis C composition is used for inhibiting hepatitis C virus or treating hepatitis C. The invention also provides a method for treating hepatitis C and a method for preparing a drug for inhibiting hepatitis C viruses or treating hepatitis C.

摘要翻译： 本发明提供了一种抗丙型肝炎组合物，其包括：有效量的柠檬醛化合物，其中所述类柠檬醛化合物的结构显示为结构式（I）：其中R 1包含H或OAc，R 2包含H或COCH（CH 3）2; 和药学上可接受的载体或盐，抗丙型肝炎组合物用于抑制丙型肝炎病毒或治疗丙型肝炎。本发明还提供了一种治疗丙型肝炎的方法和一种制备用于抑制丙型肝炎病毒或 治疗丙型肝炎

公开(公告)号：US20120121744A1

公开(公告)日：2012-05-17

申请号：US13167453

申请日：2011-06-23

申请人： Chuang-Chun CHIUH ,  Shin-Ru SHIH ,  Shau-Feng CHANG ,  Yi-Hsiang CHEN ,  I-Chen HU

发明人： Chuang-Chun CHIUH ,  Shin-Ru SHIH ,  Shau-Feng CHANG ,  Yi-Hsiang CHEN ,  I-Chen HU

IPC分类号： A61K35/74 ,  A61P31/16 ,  C12N1/20

CPC分类号： C12N1/12 ,  A61K35/748 ,  C12N1/04

摘要： Disclosed is a pharmaceutical composition for inhibiting infection and replication of influenza A and B virus, and the manufacture thereof. The pharmaceutical composition is produced by a manufacture of low-temperature disintegrating cyanobacteria, comprising the steps of: (a) mixing cyanobacteria and non-organic solvent to form a suspension containing cyanobacteria; (b) freezing the suspension with a temperature below 0° C. to form a ice block and the ice block being melted at a low temperature, the whole step being repeated at least twice; (c) separating the cyanobacterial residues and extract solution of the suspension; and (d) collecting the isolated cyanobacterial extract solution; wherein the cyanobacterial extract solution is a solution containing cyanobacterial bioactive substances. The pharmaceutical composition is able to effectively inhibit binding of sialic acid and hemagglutinin of influenza A and/or B virus, so as to inhibit infection and replication of influenza virus. Further, this pharmaceutical composition is able to inhibit infection of influenza virus resistant to neuraminidase inhibitors.

摘要翻译： 公开了用于抑制A型和B型流感病毒感染和复制的药物组合物及其制造方法。 药物组合物是通过低温崩解蓝细菌的制造而制造的，包括以下步骤：（a）将蓝细菌和非有机溶剂混合以形成含有蓝细菌的悬浮液; （b）将温度低于0℃的悬浮液冷冻，形成冰块，冰块在低温下熔化，整个步骤重复至少两次; （c）分离悬浮液中的蓝藻残渣并提取溶液; 和（d）收集孤立的蓝藻提取物溶液; 其中蓝藻提取物溶液是含有蓝藻生物活性物质的溶液。 药物组合物能够有效抑制唾液酸和甲型流感病毒和/或B型病毒血凝素的结合，从而抑制流感病毒的感染和复制。 此外，该药物组合物能够抑制对神经氨酸酶抑制剂有抗性的流感病毒感染。